Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Circle Pharma announced that two poster presentations at the American Association for Cancer Research Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers.